The latest in smarter trials

As a not-for-profit, our mission is to enable whole-system change in clinical trials. This means sharing our approach and knowledge with our community. From news about Protas, our partnerships and trials, to advice and guidance, discover more about our world.

An image of Adenike Baker on a dark green background

Opinion 09 March 2023

Celebrating International Women’s Day: Adenike Baker

Hear from some of the women behind our work at Protas in this IWD series.

An image of Dr Beth Thompson on a green background

Opinion 08 March 2023

Celebrating International Women’s Day: Dr Beth Thompson MBE

Hear from some of the women behind our work at Protas in this IWD series.

An image of Adrian Hernandez and Martin Landray

News 01 March 2023

Protas partners with Duke Clinical Research Institute

The partnership aims to transform the quality, accessibility and affordability of randomised clinical trials for common health conditions.

Report 23 February 2023

“New National Purpose”: Protas named in Blair-Hague report on innovation

Protas named in report by William Hague and Tony Blair on harnessing innovation in science and tech.

News 31 January 2023

Protas signs strategic partnership with Moderna

Moderna is a leading biotechnology company pioneering mRNA. Its mission is to deliver the greatest possible impact to people.

News 09 January 2023

Protas IT contract awarded to Slalom

Protas awards the contract to develop and operate a unified clinical trials management platform to Slalom.

News 16 November 2022

Protas signs strategic collaboration with Regeneron

Protas and Regeneron, the leading biotechnology company, announce a strategic, long-term collaboration.

News 27 October 2022

Protas announces grant funding from Flu Lab

Protas has announced a £5 million grant from Flu Lab, a charitable organisation fuelling bold approaches to defeat influenza.

News 17 October 2022

Protas appoints Dr Beth Thompson MBE to its board

Protas is pleased to announce the appointment of Dr Beth Thompson MBE to its Board of Directors.

1 2 3 4 5 6 7